Effects of Arginase Inhibition in Hypertensive Hyperthyroid Rats

Am J Hypertens. 2015 Dec;28(12):1464-72. doi: 10.1093/ajh/hpv049. Epub 2015 Apr 23.

Abstract

Background: This study analyzed the effects of chronic administration of N[omega]-hydroxy-nor-l-arginine (nor-NOHA), an inhibitor of arginase, on the hemodynamic, oxidative stress, morphologic, metabolic, and renal manifestations of hyperthyroidism in rats.

Methods: Four groups of male Wistar rats were used: control, nor-NOHA-treated (10 mg/kg/day), thyroxine (T4)-treated (75 μg/rat/day), and thyroxine- plus nor-NOHA-treated rats. All treatments were maintained for 4 weeks. Body weight, tail systolic blood pressure (SBP), and heart rate (HR) were recorded weekly. Finally, morphologic, metabolic, plasma, and renal variables were measured. Arginase I and II protein abundance and arginase activity were measured in aorta, heart, and kidney.

Results: The T4 group showed increased arginase I and II protein abundance, arginase activity, SBP, HR, plasma nitrates/nitrites (NOx), brainstem and urinary isoprostanes, proteinuria and cardiac and renal hypertrophy in comparison to control rats. In hyperthyroid rats, chronic nor-NOHA prevented the increase in SBP and HR and decreased proteinuria in association with an increase in plasma NOx and a decrease in brainstem and urinary isoprostanes. In normal rats, nor-NOHA treatment did not significantly change any hemodynamic, morphologic, or renal variables. Acute nor-NOHA administration did not affect renal or systemic hemodynamic variables in normal or T4-treated rats.

Conclusion: Hyperthyroidism in rats is associated with the increased expression and activity of arginase in aorta, heart, and kidney. Chronic arginase inhibition with nor-NOHA suppresses the characteristic hemodynamic manifestations of hyperthyroidism in association with a reduced oxidative stress. These results indicate an important role for arginase pathway alterations in the cardiovascular and renal abnormalities of hyperthyroidism.

Keywords: arginase activity; blood pressure; hypertension; hyperthyroidism; nor-NOHA; oxidative stress..

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arginase / antagonists & inhibitors*
  • Arginase / metabolism
  • Arginine / analogs & derivatives*
  • Arginine / pharmacology
  • Arginine / therapeutic use
  • Blood Pressure
  • Brain Stem / metabolism
  • Drug Evaluation, Preclinical
  • Heart Rate
  • Hypertension / drug therapy*
  • Hypertension / etiology
  • Hypertension / metabolism
  • Hyperthyroidism / complications
  • Hyperthyroidism / drug therapy*
  • Hyperthyroidism / metabolism
  • Isoprostanes / urine
  • Male
  • Nitric Oxide / blood
  • Random Allocation
  • Rats, Wistar
  • Renal Circulation / drug effects
  • Thyroid Hormones / blood

Substances

  • Isoprostanes
  • N(omega)-hydroxynorarginine
  • Thyroid Hormones
  • Nitric Oxide
  • Arginine
  • Arginase